Marvisi, Chiara
 Distribuzione geografica
Continente #
AS - Asia 3.147
NA - Nord America 2.789
EU - Europa 1.700
SA - Sud America 434
AF - Africa 67
OC - Oceania 14
Totale 8.151
Nazione #
US - Stati Uniti d'America 2.721
SG - Singapore 1.077
CN - Cina 959
IT - Italia 516
HK - Hong Kong 347
BR - Brasile 345
VN - Vietnam 309
DE - Germania 217
GB - Regno Unito 213
FI - Finlandia 193
KR - Corea 155
RU - Federazione Russa 124
SE - Svezia 100
FR - Francia 88
NL - Olanda 49
ID - Indonesia 44
IN - India 44
IE - Irlanda 38
BD - Bangladesh 36
AR - Argentina 34
AT - Austria 31
CA - Canada 29
IQ - Iraq 29
MX - Messico 29
JP - Giappone 25
LT - Lituania 22
MA - Marocco 20
BG - Bulgaria 19
PL - Polonia 19
TR - Turchia 19
UA - Ucraina 14
AU - Australia 13
CL - Cile 13
PK - Pakistan 13
KW - Kuwait 12
ZA - Sudafrica 12
AE - Emirati Arabi Uniti 10
EC - Ecuador 10
DZ - Algeria 9
ES - Italia 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
PE - Perù 8
PT - Portogallo 8
CZ - Repubblica Ceca 7
PH - Filippine 7
TW - Taiwan 7
VE - Venezuela 7
CO - Colombia 6
IL - Israele 6
KE - Kenya 6
AZ - Azerbaigian 5
GR - Grecia 5
AL - Albania 4
EG - Egitto 4
LB - Libano 4
MY - Malesia 4
PY - Paraguay 4
TH - Thailandia 4
TN - Tunisia 4
UY - Uruguay 4
BE - Belgio 3
CH - Svizzera 3
CR - Costa Rica 3
KG - Kirghizistan 3
LV - Lettonia 3
MT - Malta 3
RS - Serbia 3
AM - Armenia 2
ET - Etiopia 2
GY - Guiana 2
KZ - Kazakistan 2
SN - Senegal 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KY - Cayman, isole 1
LI - Liechtenstein 1
MD - Moldavia 1
MG - Madagascar 1
MU - Mauritius 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
RO - Romania 1
Totale 8.146
Città #
Santa Clara 679
Singapore 672
Hefei 501
Hong Kong 343
Ashburn 327
San Jose 264
Helsinki 168
Seoul 153
London 132
Munich 129
Beijing 118
Ho Chi Minh City 104
Chandler 101
The Dalles 83
Fairfield 81
Los Angeles 72
Hanoi 69
Milan 64
Nyköping 64
Dallas 56
Chicago 54
Moscow 50
Lauterbourg 49
New York 44
Council Bluffs 38
Dublin 37
Jakarta 34
São Paulo 33
Bologna 32
Seattle 31
Buffalo 30
Shanghai 29
Kent 28
Houston 27
Salt Lake City 27
Cambridge 26
Nuremberg 25
Wilmington 24
Rome 23
San Diego 23
Woodbridge 23
Frankfurt am Main 22
Orem 18
Haiphong 17
Portsmouth 17
Redondo Beach 17
Rio de Janeiro 17
Amsterdam 15
Atlanta 15
Princeton 15
Tokyo 15
Modena 14
Bremen 13
Lappeenranta 13
Vienna 13
Florence 12
Kuwait City 12
Tampa 12
Da Nang 11
Elk Grove Village 11
Sofia 11
Boardman 10
Brooklyn 10
Reggio Emilia 10
Ankara 9
Denver 9
Manchester 9
Melbourne 9
Mexico City 9
Tashkent 9
Turku 9
Warsaw 9
Ann Arbor 8
Baghdad 8
Chennai 8
Des Moines 8
Ksawerów 8
Montreal 8
Padova 8
San Francisco 8
Santiago 8
Toronto 8
Brasília 7
Campinas 7
Casablanca 7
Columbus 7
Curitiba 7
Guangzhou 7
Lancaster 7
Naples 7
Palermo 7
Thái Bình 7
Turin 7
Biên Hòa 6
Boston 6
Brescia 6
Dearborn 6
Düsseldorf 6
Fortaleza 6
Lima 6
Totale 5.458
Nome #
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 302
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 289
EULAR guidelines on ANCA-associated vasculitis in the real life 264
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 207
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 200
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 195
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 195
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 190
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 187
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 187
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 174
EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS 169
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 168
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 161
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 159
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 158
EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 154
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 154
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 154
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 152
117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 150
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 150
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 145
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 145
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 144
Development of the Takayasu Arteritis Integrated Disease Activity Index 142
The management of large vessel vasculitides 140
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 139
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis 139
What to Know About Biopsy Sampling and Pathology in Vasculitis? 135
Eosinophilic giant cell arteritis: A different subset of disease? 135
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 134
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 134
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 131
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 129
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 129
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 128
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 123
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 122
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 122
The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis 120
Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis 117
Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases 116
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 115
Comment on: Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Reply 115
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 110
Reply 109
Comparing treatment options for large vessel vasculitis 108
Systemic vasculitis: one year in review 2024 101
Vasculitis, fibromuscular dysplasia or hereditary aneurysms? 100
PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 89
Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease 87
Reply to Comment on: Vasculitis, fibromuscular dysplasia or hereditary aneurysms? by Marvisi et al 86
The geographic and clinical clusters of Behçet’s syndrome 84
Manifestations of Skull Base IgG4‐Related Disease: A Multi‐Institutional Study 83
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 70
Hypereosinophilia and eosinophilic arterial aneurysm: not only eosinophilic granulomatosis with polyangiitis 63
Is immunotherapy safe and effective in patients with VEXAS syndrome? 12
Totale 8.220
Categoria #
all - tutte 33.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.649


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 5 7 16
2021/2022258 12 24 19 8 11 23 10 13 23 19 46 50
2022/2023483 35 47 28 20 69 51 33 52 60 22 38 28
2023/2024499 14 28 13 62 47 59 65 54 17 33 55 52
2024/20252.752 45 22 89 170 518 449 281 89 327 146 334 282
2025/20264.079 415 260 444 523 543 251 612 193 497 341 0 0
Totale 8.220